+
Site Tour

EuroEcho 2021: Advances to optimize tricuspid regurgitation management: the evidence

Maurizio Taramasso presents on the clinical and real-world outcomes from the TRILUMINATE trial and TriClip™ bRIGHT study, respectively.

Related Videos

M-TEER: patient selection and current evidence

AV Valves Summit 2024 | Closing of Day 2

EuroPCR 2021: Advancing solutions for tricuspid regurgitation patients

Echo course mitral TEER – cases

Navitor™: Voice of the Experts Mohammed Saad

EuroPCR 2023: Mitral regurgitation

ESC 2023 HF Satellite Symposium

Navitor™: Voice of the Experts Maurizio Taramasso

TRENDING TOPICS

Amplatzer™ Amulet™ LAA Occluder

Why Amulet™ LAAO: A Case-Based Review with top experts

A. Shah, D. Shah, O.de Backer

EACTS 2024 - Novel approaches for Valvular and LVAD therapies

Reconsidering current approaches to valve and LVAD therapies

Early outcomes on Epic Max platform

Cleveland clinic (US) experience: Early outcomes and a perspective on porcine vs. bovine

CONNEXT


HUB
RELATED RESOURCES

PCRLV 2022: bRIGHT 30 days

ACC 2023: COAPT™ trial

EuroEcho 2021: Tricuspid regurgitation: The Patient

ESC 2022: FMR

CONNEXT


LIVE
RELATED EVENTS

Screening Transmission | Mitral focus

AV VALVES 2023: TR – Multileaflet Valve

AV VALVES 2023: TA, TF in TMVR

TAVI Summit 2023: Aortic stenosis

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline